MedTrace Logo

Beta-Lactams Dosing In Pneumonia in ICU in Patients Treated by Continuous Renal Replacement Therapy: the BLIPIC Study

NCT03897582 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 65

Last updated 2024-02-02

No results posted yet for this study

Summary

Pneumonia are the most frequent infections in ICU. Little is known about beta-lactam doses necessary for this infection for patients treated with continuous veino-veinous hemodialysis. The pharmacokinetic variability expose to over and underdosage leading to toxicity or therapeutic failure. The aim of this study is to define if beta-lactams doses used in pneumonia for patients with acute kidney injury treated with our hemodialysis conditions lead to beta-lactam therapeutic plasma levels.

Conditions

  • Beta-lactam
  • Continuous Renal Replacement Therapy
  • Pneumonia
  • Antibiotic

Sponsors & Collaborators

  • Centre Hospitalier de Lens

    collaborator OTHER

  • Centre Hospitalier de Bethune

    collaborator NETWORK

  • University Hospital, Lille

    collaborator OTHER

  • General Hospital of Douai

    collaborator OTHER

  • Centre hospitalier de Boulogne

    collaborator UNKNOWN

  • Centre Hospitalier de Valenciennes

    lead NETWORK

Principal Investigators

  • Fabien Lambiotte, MD · Centre Hospitalier de Valenciennes

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-02-22
Primary Completion
2026-05-31
Completion
2026-05-31

Countries

  • France

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03897582 on ClinicalTrials.gov